10-Q: Cocrystal Pharma Advances Antiviral Pipeline, Faces Going Concern

Cocrystal Pharma reported reduced net losses and R&D expenses while advancing its influenza and norovirus/coronavirus programs, but faces substantial doubt about its ability to continue as a going concern.

Summary

• Net loss significantly decreased to $6,405,000 for the nine months ended September 30, 2025, from $14,238,000 in the prior year.
• Research and development expenses decreased by $7,064,000 to $3,436,000 for the nine months ended September 30, 2025, primarily due to clinical trials winding down.
• General and administrative expenses decreased by $1,046,000 to $3,102,000 for the nine months ended September 30, 2025, mainly due to reduced compensation and legal costs.
• Cash and restricted cash stood at $7,804,000 as of September 30, 2025, down from $9,935,000 at December 31, 2024.
• The company raised $4,337,000 in net proceeds from financing activities during the nine months ended September 30, 2025, including a registered direct offering and ATM sales.
• Management believes current resources are insufficient to fund operations beyond the next 12 months, raising substantial doubt about the company's ability to continue as a going concern.
• Completed Phase 2a human challenge study for oral CC-42344 (influenza A) with favorable safety and tolerability.
• Completed Phase 1 study for oral CDI-988 (norovirus/coronavirus) with favorable safety and tolerability, and received FDA "Study May Proceed Letter" for a Phase 1b norovirus challenge study.
• Received a $500,000 SBIR Phase I award from NIH/NIAID for a novel influenza A and B antiviral candidate.
• Conducted a private placement of securities to four insiders on October 28, 2025, raising $1,030,000 gross proceeds.

Sentiment

Score: 3

Explanation: While the company has made notable progress in its clinical development programs for influenza and norovirus/coronavirus candidates, including positive Phase 1 and Phase 2a results and an FDA "Study May Proceed" letter, the severe "going concern" warning and the explicit statement that current resources are insufficient for the next 12 months present a significant financial challenge. The capital raises provide temporary relief but highlight the ongoing need for external funding and result in dilution.

Positives

• Significant reduction in net loss for the nine months ended September 30, 2025, to $6,405,000 from $14,238,000 in the prior year.
• Substantial decrease in research and development expenses by $7,064,000, reflecting progress in clinical trials.
• Successful completion of Phase 2a human challenge study for oral CC-42344 (influenza A) with favorable safety and tolerability, and no serious adverse events.
• Successful completion of Phase 1 study for oral CDI-988 (norovirus/coronavirus) demonstrating favorable safety and tolerability across all tested doses.
• Received FDA "Study May Proceed Letter" for a Phase 1b challenge study evaluating oral CDI-988 for norovirus prophylaxis and treatment.
• Demonstrated in vitro efficacy of CC-42344 against the highly pathogenic H5N1 avian influenza A strain.
• Received a $500,000 Small Business Innovation Research (SBIR) Phase I award from NIH/NIAID for a novel influenza A and B antiviral candidate.
• Secured $4,337,000 in net proceeds from financing activities during the nine months ended September 30, 2025, improving liquidity.

Negatives

• Incurred a net loss of $6,405,000 for the nine months ended September 30, 2025, and negative operating cash flows of $6,456,000 for the same period.
• Management has concluded that there is substantial doubt about the company's ability to continue as a going concern, as current resources are not sufficient to fund operations beyond the next 12 months.
• The company has historically not generated sustained positive cash flow and has no products approved for sale.
• The At-The-Market (ATM) offering agreement sales were terminated on September 12, 2025, limiting a previous source of capital.
• Future funding is uncertain, with no assurances that additional capital will be sufficient or obtainable on acceptable terms, potentially leading to delays or elimination of R&D programs.
• The company expects to continue incurring substantial operating losses and negative cash flows over the next several years.

Risks

• Going Concern: Substantial doubt about the company's ability to continue as a going concern due to accumulated net losses and negative operating cash flows, with current resources insufficient to fund operations beyond the next 12 months.
• Funding Risk: Inability to secure additional funding when needed, which could lead to delays, reduction in scope, or elimination of clinical trials or research and development programs.
• Regulatory Approval Risk: Products in development require clearances from the U.S. FDA and other international regulatory agencies, which may not be received, or could be delayed, materially impacting the business.
• Competition: Exposure to rapid technological change, competition from currently available treatments and therapies, and competition from larger companies.
• Intellectual Property: Challenges in effective protection of proprietary technology.
• Dependence on Key Individuals: Reliance on key personnel for successful operations.
• Economic Conditions: Risks arising from inflation, central bank interest rates, deterioration of the job market, possibility of recession, and the economic impact of global conflicts (Israel and Ukraine).
• Supply Chain Disruptions: Manufacturing and research delays due to raw materials and labor shortages, supply chain disruptions, and other business interruptions affecting vendors, CROs, and CMOs.
• Clinical Trial Risks: General risks associated with clinical trials, including adverse findings or delays, and the ability of CROs to recruit volunteers.
• Viral Mutations: Potential mutations in target viruses (e.g., SARS-CoV-2) that may result in variants resistant to product candidates.

Future Outlook

The company plans to continue the development of oral CC-42344 for pandemic and seasonal influenza A. The Phase 1b norovirus challenge study for oral CDI-988 is expected to begin during the first half of 2026. The company aims for ultra-short (four to six weeks) combination oral treatments for Hepatitis C with CC-31244, and is seeking a partner for its further clinical development. Management expects to continue incurring substantial operating losses and negative cash flows over the next several years during clinical development phases and will need to raise additional capital to fund future operations.

Management Comments

• "We believe that our current resources will not be sufficient to fund our operations beyond the next 12 months."
• "Management has concluded that there is substantial doubt about the Company's ability to continue as a going concern."
• "We plan to continue development of oral CC-42344 as a treatment for pandemic and seasonal influenza A."
• "We expect that the oral CDI-988 Phase 1 data will support future norovirus and coronavirus studies."
• "Management intends to fund future operations through additional private or public equity offerings and through arrangements with strategic partners or from other sources."

Industry Context

Cocrystal Pharma operates in the highly competitive antiviral drug development space, targeting significant global public health problems like influenza, norovirus, and coronaviruses (including COVID-19), as well as Hepatitis C. The company's focus on novel, broad-spectrum antiviral candidates with unique mechanisms of action (e.g., PB2 inhibitor for influenza, protease inhibitor for noro/coronaviruses) positions it against existing treatments that face resistance issues (e.g., Tamiflu, Xofluza for influenza) and areas with no effective treatments or vaccines (norovirus). The pursuit of ultra-short HCV treatments aligns with an industry trend towards improved patient compliance and reduced treatment duration, though the market is already competitive with several approved direct-acting antiviral agents. The SBIR award highlights governmental interest in novel antiviral solutions.

Comparison to Industry Standards

• Influenza Antivirals: Current approved treatments like oseltamivir phosphate (Tamiflu), zanamavir (Relenza), and baloxavir marboxil (Xofluza) are burdened with significant viral resistance. Cocrystal's CC-42344, a novel PB2 inhibitor, aims to address this by binding to a highly conserved site and showing activity against Tamiflu and Xofluza resistant strains, potentially offering an advantage over existing therapies.
• Norovirus Treatment: There is currently no effective treatment or vaccine for norovirus. Cocrystal's CDI-988, a novel protease inhibitor, is in Phase 1b development, positioning it as a potential first-in-class therapeutic in a market with a significant unmet medical need. Competitors like Vaxart Pharmaceutical, Moderna, Hillevax, Takeda Pharmaceuticals, Anhui Zhifei Longcom Biopharmaceutical (China), and National Vaccine and Serum Institute (China) are developing vaccines, but not treatments.
• Coronavirus Treatment: The market has approved antivirals like Veklury (remdesivir) and Paxlovid (nirmatrelvir/ritonavir), and other therapeutics under EUA. Cocrystal's CDI-988, also a protease inhibitor, targets a highly conserved region, aiming for broad-spectrum activity against SARS-CoV-2 and its variants, similar to Paxlovid's mechanism but potentially with broader coverage.
• Hepatitis C Treatment: The HCV market is competitive with several approved direct-acting antiviral agents (DAAs) like Harvoni, Viekira Pak, Epclusa, Zepatier, and Mavyret, typically requiring 8-12 weeks of treatment. Cocrystal's CC-31244 aims for ultra-short combination oral treatments of four to six weeks, which would be a significant improvement over current standards, as no competing company has yet achieved a short HCV treatment of less than 8 weeks with a high (>95%) sustained virologic response (SVR) at week 12.

Corporate Governance

Legal Proceedings

• No material changes to the description of legal proceedings set forth in the Annual Report on Form 10-K for the year ended December 31, 2024.

Related Party Transactions

• Entered into a three-year lease extension on August 14, 2024, for office space in Miami, Florida, with a limited liability company controlled by Dr. Phillip Frost, a director and principal stockholder.
• Operating lease expense to this related party was $48,000 for the nine months ended September 30, 2025.

Stakeholder Impact

• Shareholders: Significant dilution from recent equity offerings (ATM, registered direct offering, private placement to insiders) and potential future dilution due to ongoing capital needs. The "going concern" warning poses a substantial risk to investment value.
• Employees: Continued R&D activities and new equity incentive plan (2025 Plan) may offer stability and incentives, but the overall financial uncertainty could impact job security.
• Customers (future): Progress in clinical trials for influenza and norovirus/coronavirus candidates offers potential for new treatments for significant public health issues.
• Creditors: The "going concern" warning indicates increased risk for creditors.
• Suppliers/CROs: Continued R&D spending, though reduced, indicates ongoing engagement, but financial instability could pose payment risks.

Next Steps

• Continue development of oral CC-42344 as a treatment for pandemic and seasonal influenza A.
• Initiate Phase 1b challenge study for oral CDI-988 for norovirus prophylaxis and treatment during the first half of 2026.
• Seek a partner for further clinical development of CC-31244 for Hepatitis C.
• Obtain additional capital through private or public equity offerings or strategic partnerships to fund future operations.

Key Dates

Recommendation

The explicit "substantial doubt about the Company's ability to continue as a going concern" is a critical red flag for investors. While there is some positive R&D progress, the company's inability to fund operations beyond 12 months with current resources, coupled with continuous net losses and negative cash flows, indicates a highly precarious financial position. The recent capital raises, including a private placement to insiders, provide only temporary relief and come with significant dilution. The long path to profitability for a clinical-stage biopharmaceutical company, combined with the severe liquidity issues, makes this a high-risk investment with a strong likelihood of further value erosion for existing shareholders.

Keywords

Antiviral drug development, Biopharmaceutical, Clinical stage, Influenza A, Norovirus, Coronavirus, COVID-19, Hepatitis C, CC-42344, CDI-988, Drug discovery, SEC filing, 10-Q, Going concern, Clinical trials, Biotech, Pharmaceuticals